Global Clinical Trial Kits Market (2021-2028)

Dublin, October 08, 2021 (GLOBE NEWSWIRE) – The Clinical Trial Kits Market Size, Share and Trend Analysis Report by Department (Kit Solutions, Logistics), by Phase (Phase I, Phase II, Phase III, Phase IV), by Region and segment forecast, 2021-2028 “ report was added to ResearchAndMarkets.com offer.

The global clinical trial kits market size is expected to reach $ 2.5 billion by 2028, according to a new report from the publisher. The market is expected to grow at a CAGR of 8.5% from 2021 to 2028. Factors driving the market expansion include globalization of clinical trials, increasing demand for remote services, and increasing complexity of trials. clinics.

Remote clinical trial services are becoming increasingly essential in terms of patient retention, satisfaction and safety. To enhance their capabilities, pharmaceutical companies have established a relationship with global logistics partners to provide direct services to patients. These services provide participants with the flexibility and convenience of participating in trials while staying at home.

The COVID-19 pandemic has affected the market, which has slowed down the testing process. The COVID-19 pandemic is rapidly spurring advancements in medical practices that allow people to remotely connect to the healthcare system. This effort to examine patients at home has sparked interest in home sample collection and testing. These services are convenient and minimize the potential exposure to SARS-CoV-2.

Companies have started offering digital direct testing services to consumers. Other aspects of the testing process, from ordering tests to collecting samples, are already making their way into patient homes. In addition, regulatory authorities instantly gave sponsors directions to address issues that arose during ongoing clinical studies. Changes such as the use of telemedicine, the elimination of non-essential laboratory visits and assessments, as well as diagnostic testing and sample collection, have allowed many studies to continue while ensuring the patient safety during the pandemic.

Highlights of the Clinical Trial Kits Market Report

  • The logistics segment dominated the market and accounted for the largest revenue share of 54.9% in 2020. This is due to the increasing demand for services to simplify the logistics process in clinical trials.

  • Phase III segment dominated the market and accounted for the largest revenue share of 53.4% ​​in 2020 as phase III trials require large numbers of participants

  • North America dominated the market in 2020 due to favorable government support and the existence of a large number of companies offering innovative services in the United States.

  • In Asia-Pacific, the market is expected to experience the highest CAGR of 9.9% during the forecast period as the region keeps growing in terms of clinical trials due to the large population and technology. in development.

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trial Kits Market: Variables, Trends and Scope
3.1 Market Lineage Outlook
3.1.1 Parents’ Market Outlook
3.1.2 Auxiliary Market Outlook
3.2 Mapping of penetration and growth prospects
3.3 Market dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Globalization of clinical trials
3.3.1.2 Growing demand for remote services
3.3.1.3 Growing complexity of clinical trials
3.3.2 Analysis of market restrictions
3.3.2.1 Different regulations depending on the country
3.4 Analysis Tools of the Clinical Trial Kits Market
3.4.1 Porter’s five forces analysis
3.4.2 PESTEL analysis
3.4.3 Major transactions and strategic alliances
3.4.3.1 Acquisition
3.4.3.2 Partnerships
3.4.3.3 Enlargement
3.4.3.4 Product launch
3.4.3.5 Collaboration
3.5 Clinical Trial Kits Market: Total Addressable Market (TAM) Analysis
3.5.1 Market Overview

Chapter 4 Impact of Covid-19
4.1 Impact of COVID-19 on the market
4.2 Impact of COVID-19 on logistics
4.3 Impact of the COVID-19 pandemic on clinical trial activity
4.3.1 Barriers to Clinical Trials
4.3.2 Discontinued clinical trials
4.3.2.1 Companies with Phase I trial interruption
4.3.2.2 Companies with Phase 2 trial interruption
4.3.2.3 Companies with Phase 3 trial interruption

Chapter 5 Clinical Trial Kits Market: Service Segment Analysis
5.1 Clinical trial kits: market share analysis, 2020 and 2028
5.2 Assembly solutions
5.2.1 Kitting Solutions Market, 2016-2028 (USD Million)
5.2.2 Drug kits
5.2.2.1 Drug Kits Market, 2016-2028 (USD Million)
5.2.3 Sample collection kits
5.2.3.1 Sample Collection Kits Market, 2016-2028 (USD Million)
5.3 Logistics
5.3.1 Logistics Market, 2016-2028 (USD Million)
5.3.2 Transport
5.3.2.1 Transportation Market, 2016-2028 (USD Million)
5.3.3 Warehousing and storage
5.3.3.1 Warehousing and Storage Market, 2016-2028 (USD Million)
5.3.4 Others
5.3.4.1 Other markets, 2016 – 2028 (USD million)

Chapter 6 Clinical Trial Kits Market: Phase Segment Analysis
6.1 Clinical Trial Kits: Market Share Analysis, 2020 and 2028
6.2 Phase I
6.2.1 Phase I Market, 2016-2028 (USD Million)
6.3 Phase II
6.3.1 Phase II Market, 2016 – 2028 (USD Million)
6.4 Phase III
6.4.1 Phase III Market, 2016-2028 (USD Million)
6.5 Phase IV
6.5.1 Phase IV Market, 2016-2028 (USD Million)

Chapter 7 Clinical Trial Kits Market: Regional Analysis

Chapter 8 Competitive Landscape
8.1 Company profiles
8.1.1 Brooks Life Sciences
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Benchmarking of services
8.1.1.4 Strategic initiatives
8.1.2 Q2 solutions
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Benchmarking of services
8.1.2.4 Strategic initiatives
8.1.3 Patheon (Thermo Fisher Scientific Inc)
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 ServicebBenchmarking
8.1.4 Labcorp Drug Development
8.1.4.1 Company overview
8.1.4.2 financial performance
8.1.4.3 Benchmarking of services
8.1.4.4 Strategic initiatives
8.1.5 Charles River Laboratories
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Benchmarking of services
8.1.6 LAbConnect
8.1.6.1 Company overview
8.1.6.2 Benchmarking of services
8.1.6.3 Strategic initiatives
8.1.7 Almac Group
8.1.7.1 Company overview
8.1.7.2 Benchmarking of services
8.1.7.3 Strategic initiatives
8.1.8 Precision Medicine Group
8.1.8.1 Company overview
8.1.8.2 Benchmarking of services
8.1.8.3 Strategic initiatives
8.1.9 Cerba search
8.1.9.1 Company overview
8.1.9.2 Benchmarking of services
8.1.10 Alpha Laboratories
8.1.10.1 Company overview
8.1.10.2 Benchmarking of services
8.1.11 Marking a UPS Company
8.1.11.1 Company overview
8.1.11.2 Benchmarking of services
8.1.11.3 Strategic initiatives
8.1.12 Clinogen
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Benchmarking of services
8.1.12.4 Strategic initiatives

For more information on this report, visit https://www.researchandmarkets.com/r/lbz1ty

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

Father set up a home lab to make life-saving medicine for his son

How far would you go to save your child’s life? Haoyang was born in Kunming …

Leave a Reply

Your email address will not be published. Required fields are marked *